Cargando…

Smoldering Multiple Myeloma

Smoldering multiple myeloma (SMM) is an asymptomatic precursor stage of multiple myeloma (MM) characterized by clonal bone marrow plasma cells (BMPC) ≥ 10% and/or M protein level ≥ 30 g/L in the absence of end organ damage. It represents an intermediate stage between monoclonal gammopathy of undeter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Minjie, Yang, Guang, Kong, Yuanyuan, Wu, Xiaosong, Shi, Jumei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4426782/ https://www.ncbi.nlm.nih.gov/pubmed/26000300 http://dx.doi.org/10.1155/2015/623254

Ejemplares similares

Early versus Deferred Treatment for Smoldering Multiple Myeloma: A Meta-Analysis of Randomized, Controlled Trials
por: Gao, Minjie, et al.
Publicado: (2014)

Multiple myeloma cancer stem cells
por: Gao, Minjie, et al.
Publicado: (2016)

Recent Advances in the Management of Smoldering Multiple Myeloma
por: Madhira, Bhaskara Reddy, et al.
Publicado: (2020)

What Is New in the Treatment of Smoldering Multiple Myeloma?
por: Bolli, Niccolo’, et al.
Publicado: (2021)

Risk Stratification and Treatment in Smoldering Multiple Myeloma
por: Lussier, Tyler, et al.
Publicado: (2021)

Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?
por: Kim, E. Bridget, et al.
Publicado: (2020)

Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2
por: Gao, Lu, et al.
Publicado: (2015)

Smoldering Multiple Myeloma Arising in Ulcerative Colitis
por: Yang, Xue, et al.
Publicado: (2018)

Genomic patterns of progression in smoldering multiple myeloma
por: Bolli, Niccolò, et al.
Publicado: (2018)

Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma
por: Markus, Efrat, et al.
Publicado: (2020)

Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2020)

Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?
por: Lionetti, Marta, et al.
Publicado: (2021)

How we manage smoldering multiple myeloma
por: Romano, Alessandra, et al.
Publicado: (2020)

How We Approach Smoldering Multiple Myeloma
por: Raje, Noopur, et al.
Publicado: (2020)

Systemic Mastocytosis Associated with “Smoldering” Multiple Myeloma
por: Zanelli, Magda, et al.
Publicado: (2021)

How I approach smoldering multiple myeloma
por: Vaxman, Iuliana, et al.
Publicado: (2022)

Smoldering multiple myeloma current treatment algorithms
por: Rajkumar, S. Vincent, et al.
Publicado: (2022)

Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
por: Blum, Agnieszka, et al.
Publicado: (2018)

The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma
por: Zamagni, Elena, et al.
Publicado: (2020)

Prevalence, incidence and survival of smoldering multiple myeloma in the United States
por: Ravindran, A, et al.
Publicado: (2016)

Systemic Mastocytosis with Smoldering Multiple Myeloma: Report of a Case
por: Ghanem, Sassine, et al.
Publicado: (2016)

Smoldering multiple myeloma revealed by superior ophthalmic vein thrombosis
por: Bouattour, Nadia, et al.
Publicado: (2020)

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
por: Mateos, María-Victoria, et al.
Publicado: (2020)

The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
por: Boyle, Eileen M., et al.
Publicado: (2021)

Kidney transplantation for active multiple myeloma or smoldering myeloma: a case–control study
por: Kormann, Raphaël, et al.
Publicado: (2019)

Is aggressive treatment of smoldering myeloma the path to curing myeloma?
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients
por: Rajkumar, S, et al.
Publicado: (2023)

Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I
por: Yang, Guang, et al.
Publicado: (2015)

Eosinophilic Fasciitis and Smoldering Multiple Myeloma: An Exceptional Association in Young Adults
por: Jabbouri, Rajaa, et al.
Publicado: (2022)

Gastrointestinal amyloidosis in a patient with smoldering multiple myeloma: A case report
por: Liu, Ai-Ling, et al.
Publicado: (2022)

Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
por: Lakshman, Arjun, et al.
Publicado: (2018)

Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma
por: Ravi, P, et al.
Publicado: (2016)

Novel therapies delay the progression of smoldering multiple myeloma: Case report and discussion
por: Jhaveri, A., et al.
Publicado: (2010)

Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma
por: Atrash, Shebli, et al.
Publicado: (2018)

Crohn's disease and smoldering multiple myeloma: a case report and literature review
por: Park, So Young, et al.
Publicado: (2017)

Amyloid arthropathy in smoldering myeloma: Do not take it lightly
por: Muchtar, Eli, et al.
Publicado: (2021)

Angiogenic cytokines profile in smoldering multiple myeloma: No difference compared to MGUS but altered compared to symptomatic myeloma
por: Gkotzamanidou, Maria, et al.
Publicado: (2013)

TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma
por: Tao, Yi, et al.
Publicado: (2017)

Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes
por: Bustoros, Mark, et al.
Publicado: (2022)

Ferroportin downregulation promotes cell proliferation by modulating the Nrf2–miR-17-5p axis in multiple myeloma
por: Kong, Yuanyuan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b2grp3ie06b4cjbr227mh525tv